A potential disease-modifying treatment for osteoarthritis from Cynata Therapeutics

/in ,

A potential disease-modifying treatment for osteoarthritis from Cynata Therapeutics Osteoarthritis is a chronic inflammatory joint disease that causes pain and disability, affecting over two million people in Australia and over 500 million people worldwide. Currently, there are no approved disease-modifying therapies for osteoarthritis, with treatment options limited to symptom management. Cynata is developing CYP-004, our Cymerus™ off-the-shelf iPSC-derived […]

Read more

Humanetix joins forces with Provider Assist to drive end-to-end people, business, and digital solutions.

/in , ,

Humanetix joins forces with Provider Assist to drive end-to-end people, business, and digital solutions. BioScience Managers is proud to share that portfolio company Humanetix (HX) has entered a strategic acquisition Provider Assist (PA), a leading healthcare solutions provider in Australia. This milestone represents a robust validation of Humanetix’s technology and its impact in aged […]

Read more

Adherium announces interim results from the iCare respiratory care program

/in ,

Adherium announces interim results from the iCare respiratory care program Adherium has today announced interim results from the iCARE respiratory care program, demonstrating positive clinical outcomes, including breakthrough adherence and patient engagement, whilst using Adherium’s Hailie® Smartinhaler technology. The iCARE program, conducted in partnership with Intermountain Health and CareCentra, is one of the largest real-world […]

Read more

Cynata Therapeutics release its Appendix 4E and Annual Report

/in ,

Cynata Therapeutics release its Appendix 4E and Annual Report Cynata Therapeutics has released its Appendix 4E and Annual Report, reflecting a year of strong momentum and significant progress across its clinical pipeline. As Independent Chair, Dr Geoff Brooke states, “Cynata is entering what I believe will be the most pivotal year in our history. Within […]

Read more

Adherium Conversation Series: Transforming COPD care through remote monitoring

/in ,

Adherium Conversation Series: Transforming COPD care through remote monitoring With 46 years of respiratory therapy experience, Kimberly Bennion, MsHS, RRT, CHC, FAARC, is leading the Intermountain COPD and Adult Asthma Remote Evaluation Study, a groundbreaking USD $5M research initiative focused on improving care for vulnerable pulmonary patients. Using Adherium’s Hailie® Smartinhaler® technology, Kimberly’s team is […]

Read more

Phase 2 clinical trial of CYP-001 for treating high risk acute graft-versus-host disease

/in ,

Phase 2 clinical trial of CYP-001 for treating high risk acute graft-versus-host disease Earlier this week at the Australia and New Zealand Cellular Therapy and Transplant Conference (ANZTCT), Dr Ashleigh Scott of Cynata Therapeutics presented their latest clinical progress: a Phase 2 randomised, double-blind, placebo-controlled trial of CYP-001 for high-risk acute graft-versus-host disease (HR-aGvHD). CYP-001, manufactured with its proprietary Cymerus® technology, delivers consistent, high-quality […]

Read more

Licensing partnership in Saudi Arabia for Dapsone 5% Gel

/in ,

Licensing partnership in Saudi Arabia for Dapsone 5% Gel Melbourne, Australia; 31 July 2025; Acrux Limited (ASX: ACR) Acrux has executed a Sales, Marketing, Distribution and License Agreement with Servacure Trading W.L.L. (‘Servacure’) for Dapsone 5%, Gel for Saudi Arabia. Dapsone 5%, Gel was developed Acrux and was successfully launched through a licensee in […]

Read more

Adherium conducts A$0.35m placement to institutional investor

/in ,

Adherium conducts A$0.35m placement to institutional investor Summary: Firm commitments received for A$0.35M institutional placement (before costs) at A$0.005 per share The proceeds, together with existing cash reserves and proceeds from the recent ANREO will allow Adherium toexecute on its growth plan and provide balance sheet strength. Melbourne, Australia – 4 August 2025: is pleased to announce that it has received firm commitments from sophisticated and professional investors to raise approximately A$0.35M (before costs) through an institutional placement (the “Placement”). The Placement was undertaken on the same terms as the recent partially underwritten […]

Read more